US Patent Issued to Kinase Pharma on June 10 for "Recombinant virus vector (RVV) for inhibiting epidermal growth factor receptor (EGFR) activity and method of making an agent/target cell complex to increase cetuximab-like protein (CLP) production" (Canadian Inventor)

ALEXANDRIA, Va., June 18 -- United States Patent no. 12,325,864, issued on June 10, was assigned to Kinase Pharma Inc. (Calgary, Canada).

"Recombinant virus vector (RVV) for inhibiting epidermal growth factor receptor (EGFR) activity and method of making an agent/target cell complex to increase cetuximab-like protein (CLP) production" was invented by Bradley G. Thompson (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodime...